VCFA Group Announces the Successful Close of VCFA Venture Partners VII, L.P.
Pioneering Firm Continues to Lead in Secondary Private Equity, with Succession Leadership in Place and Plans to Grow the Firm and Team Going Forward
The close of VCFA VP VII marks a significant milestone in the firm's four decades in operation. Established in 1982 by Dayton Carr, VCFA is known for being the first firm focused on secondary private equity. Dayton passed away in 2020 during the fundraise for the predecessor fund, VCFA Venture Partners VI, L.P. (VCFA VP VI). The firm commenced a succession plan with David Tom and Andrew Reilly assuming leadership and ownership of VCFA and culminating with a final closing of VCFA VP VI in
In connection with the new fundraise, VCFA is also promoting two members of the investment team.
VCFA VP VII is targeting transactions involving seasoned venture capital and growth equity assets, where the need for liquidity or portfolio realignment creates opportunities for secondary investors. These transactions are often more nuanced, requiring a deep understanding of both the operational and financial needs of portfolio companies and the intricate capital structures of these assets.
For more information on VCFA Venture Partners VII, L.P., or if you are considering selling private equity, please contact:
VCFA Group
[email protected]
212-838-5577
About VCFA Group (VCFA)
Founded in 1982, VCFA Group (VCFA) became the first firm primarily focused on the acquisition of interests in private equity funds on a secondary basis and is a pioneer in the concept of secondary purchases of limited partnership interests and GP-led transactions. To date, VCFA Group has raised eleven funds and returned over
View original content to download multimedia:https://www.prnewswire.com/news-releases/vcfa-group-announces-the-successful-close-of-vcfa-venture-partners-vii-lp-302349685.html
SOURCE VCFA Group
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
- Shape Memory Medical Secures $10 Million Financing Led by August Global Partners to Advance Aortic Clinical Programs
- Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Signs New FF Par Agreement with a Leading U.S. Robotics Distributor and Provides Details on FF EAI Robotics “Built in USA�
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share